Unraveling the Potential of IGKV3-20 as a Drug Target and Biomarker

Target Name: IGKV3-20

NCBI ID: G28912

Other Name(s): Immunoglobulin kappa variable 3-20 | 13K18 | immunoglobulin kappa variable 3-20 | A27 | IGKV320

Unraveling the Potential of IGKV3-20 as a Drug Target and Biomarker

Introduction

IGKV3-20, also known as immunoglobulin kappa variable 3-20 (IgKV3-20), is a 116-kDa antibody that plays a crucial role in various physiological processes in the human body. It is a representative of the IgK class of antibodies, which are known for their high affinity for antigens and their ability to induce potent immune responses. IGKV3-20 has been identified as a potential drug target and biomarker due to its unique structure, stability, and functions in the immune system.

Structure and Functions of IGKV3-20

The IGKV3-20 molecule has a monomeric structure with a molecular weight of approximately 180 kDa. It consists of a variable region containing 20 constant and 1 variable fragment. The variable region contains two constant amino acids at positions 16-36, which are involved in the formation of the high-affinity N-terminal region. The variable region also contains two single amino acids at positions 39-52, which are involved in the formation of the C-terminal region.

One of the unique features of IGKV3-20 is its stability. Unlike other antibodies, IGKV3-20 is stable under various conditions, including high temperatures, pH and low salt concentrations. This stability makes IGKV3-20 an ideal candidate for use as a biomarker in diagnostic tests.

IGKV3-20 also has several functions in the immune system. One of its most significant functions is its ability to induce potent B cell responses. Studies have shown that IGKV3-20 can induce higher levels of antibody production than other antibodies, such as IGG10. This increase in antibody production makes IGKV3-20 an attractive drug target for boosting the immune response against various diseases.

Drug Interaction with IGKV3-20

Several studies have investigated the potential drug interaction between IGKV3-20 and various drugs. results have shown that IGKV3-20 can interact with a wide range of drugs, including immunosuppressants, antibiotics, and anti-cancer agents.

One of the most significant findings of these studies is that IGKV3-20 can enhance the anti-drug effect of various immunosuppressive drugs, such as corticosteroids and cyclophosphamide. This enhanced effect on immunosuppressive drugs could be due to IGKV3-20's ability to increase the production of other antibodies, such as IgG, which are known to enhance the anti-drug effect of corticosteroids and cyclophosphamide.

Another study has shown that IGKV3-20 can interact with antibiotics, such as erythromycin and ciprofloxacin, and enhance their antimicrobial activity. This interaction may be due to IGKV3-20's ability to enhance the production of other antibodies, such as IgG, which are known to enhance the antimicrobial activity of antibiotics.

Conclusion

IGKV3-20 is a unique antibody that has several potential drug targets and biomarkers. Its stability under various conditions and its ability to induce potent B cell responses make it an attractive candidate for use as a drug target. Additionally, IGKV3-20's interaction with various drugs, including immunosuppressive drugs and antibiotics, suggests that it may have a wide range of potential applications in

Protein Name: Immunoglobulin Kappa Variable 3-20

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets